Abstract: The present invention provides deodorant compositions for controlling malodor from perspiration comprising a safe an effective amount of a 1,3-diketone compound having the general formula: ##STR1## wherein each W is independently selected from the group consisting of O, S and (CH.sub.2).sub.n, wherein n=1-3; and each X is independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted alkyl having from about 1 to about 5 carbon atoms, or two X moieties are covalently bonded to form a substituted or unsubstituted alkyl, heteroalkyl, aryl or heteroaryl ring having from about 3 to about 12 atoms including from 0 to about 3 heteroatoms in the ring; and a topical carrier; whereby the composition is suitable for topical application to the skin or to articles of clothing worn in the vicinity of the skin.

Abstract: The subject invention relates to pharmaceutical compositions comprising a safe and effective amount of a compound having the structure: ##STR1## wherein each R is alkyl or hydrogen, at least two being alkyl; R' is hydrogen, alkyl or aryl; R" is alkyl or halo; and each X is independently oxygen or sulfur; and a pharmaceutically-acceptable carrier. The subject invention also relates to methods for preventing damage to skin by topically applying a safe and effective amount of such compounds to the skin.

Abstract: The subject invention relates to methods of regulating skin wrinkles and/or atrophy in mammalian skin comprising topically applying to the skin of a mammal in need of treatment a composition comprising a safe and effective amount of a cyclic polyanionic polyol derivative having the structure: ##STR1## wherein n is an integer from 1 to 3; and each X is, independently, selected from the group consisting of OSO.sub.3.sup.-, OPO.sub.3.sup..dbd., SO.sub.3.sup.--, PO.sub.3.sup..dbd., CO.sub.2.sup.--, and OH; with at least 3 X's being other than OH.

Abstract: The subject invention relates to a natural sweetening composition comprising:(a) sweet juice derived from the botanical genus/species Siraitia grosvenorii, S. siamensis, S. silomaradjae, S. sikkimensis, S. africana, S. borneensis, S. taiwaniana or mixtures thereof; and(b) sugar, wherein said sugar is selected fructose, sucrose, glucose or mixtures thereof; and wherein the ratio of the sweet juice to the sugar is from about 1:1 to about 1:5. An edible acid and/or an edible salt can be added to the composition to improve the flavor. A beverage comprising an effective amount of a flavoring system and a sweetening composition is also claimed. These beverages are reduced calorie and can be supplemented with vitamins and minerals.

Abstract: The present invention involves processes preparation of a sweet juice from fruit of the Cucurbitaceae family comprising the following steps of separating peels and seeds from the juice; optionally acidifying the juices; removing off-flavor precursors from the juice; and removing a methylene chloride extractable volatiles fraction containing off-flavor materials from the juice. The present invention also involves sweet juices from the fruit of the Cucurbitaceae family comprising less than about 100 ppm (dry basis) methionine, and from about 0.1% to about 15% (dry basis) sweet terpene glycoside.

Abstract: The subject invention relates to methods for preventing or treating damage to the mucosal lining of the gastrointestinal tract of a human or lower animal by administering a safe and effective amount of a compound having the structure: ##STR1## wherein X and Y are each independently selected from O and S; R.sup.1, R.sup.2 and R.sup.3 are each independently selected from hydrogen, hydroxy, halo, unsubstituted or monosubstituted straight or branched C.sub.1 -C.sub.4 alkanyl, and unsubstituted or substituted straight or branched C.sub.1 -C.sub.4 alkanoxy; and each of R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is hydrogen or, if one or more of R.sup.1, R.sup.2 and R.sup.3 is other than hydrogen, each of R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is selected from hydrogen, halo, trifluoromethyl, and unsubstituted straight or branched C.sub.1 -C.sub.4 alkanyl.

Abstract: Disclosed are photoprotective compositions comprising a radical scavenging agent and an anti-inflammatory agent which are useful for topical application to prevent damage to skin caused by acute or chronic UV exposure. Combinations of a radical scavenging agent, an anti-inflammatory agent, and a sunscreen are also disclosed.Also disclosed is a method for using these compositions topically to prevent damage to skin caused by acute or chronic UV exposure.

Abstract: The present invention involves photoprotective compositions which are useful for topical application to prevent damage to skin caused by acute or chronic exposure to ultraviolet light comprising chelating agents having the formula ##STR1## wherein --R.sup.1 and --R.sup.2 are independently selected from the group consisting of alkyl, aryl, and heteroaryl, or R.sup.1 and R.sup.2 may be covalently bonded together to form a cyclic alkyl; --M is selected from the group consisting of =0, =S, --SR.sup.4 and --OR.sup.4 (when --M is --OR.sup.4 or --SR.sup.4, there is a hydrogen bonded to the carbon to which --M is bonded); --R.sup.4 is selected from the group consisting of hydrogen, alkyl, aryl and heteroaryl; --R.sup.3 is selected from the group consisting of hydrogen, alkyl, aryl and heteroaryl; --R.sup.6 is selected from the group consisting of hydrogen alkyl, aryl and heteroaryl; and i is selected from the group consisting of one and zero.

Abstract: The subject invention relates to methods for regulating hair growth in mammalian skin comprising topical application of diethyldithiocarbamic acid ("DEDCA") or a pharmaceutically-acceptable salt thereof. The subject invention further involves topical compositions comprising DEDCA.

Abstract: The subject invention relates to compositions and methods for regulating wrinkles in mammalian skin by topical application of a 2-deoxy- or 2-deoxy-2-halo-lysophosphatidic acid compound having the structure: ##STR1## or a pharmaceutically acceptable salt thereof, wherein --R is unsubstituted or substituted, saturated or unsaturated, straight or branched chain alkyl having from 11 to about 23 carbon atoms; each --X-- is independently --0-- or --S--; --Y-- is --0-- or --CH.sub.2 --; and Z is --H or halo.

Abstract: The present invention relates to a method for regulating wrinkles and/or atrophy in mammalian skin comprising treating the skin with a safe and effective amount of N-acetyl-L-cysteine and/or a derivative thereof.

Abstract: The subject invention relates to methods for prevention or treatment of gingivitis or periodontitis comprising topical administration, to gingival tissues of the oral cavity, of a composition comprising a safe and effective amount of a selective histamine-2 receptor antagonist compound, and oral care compositions used therefore.

Abstract: The present invention relates to compositions and methods for inhibiting plaque. In particular, this invention relates to oral compositions comprising: (a) a safe and effective amount of a carboxy-substituted polymer active agent having the formula ##STR1## or the salts thereof, wherein R is a C.sub.1 -C.sub.8 alkyl group, n is in the range of from 0 to about 2,000, m is in the range of from about 10 to about 2,000, and p is in the range of from about 1 to about 10; and (b) a pharmaceutically acceptable carrier. These compositions inhibit plaque without staining the tooth surfaces which are contacted with the composition.This invention also relates to a method of inhibiting plaque on tooth surfaces in the oral cavity. This method involves applying a safe and effective amount of the carboxy-substituted polymer active agent to the oral cavity. Such an application is typically made by applying the above-described oral compositions containing the carboxy-substituted polymer to the tooth surface.

Abstract: The present invention relates to a novel cell line isolated from a rat osteosarcoma wherein the cell line has the following characteristics: a) normal p53 gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; b) normal RB-1 gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; c) a normal c-myc gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; d) a normal c-fos gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; e) a deregulated immediate early gene response; f) a canalicular network MATRIGEL.TM.

Abstract: The present invention relates to a novel cell line isolated from a rat osteosarcoma wherein the cell line has the following characteristics: a) a mutated p53 system, b) a normal RB-1 gene as compared to a non-tumorigenic Sprague-Dawley rat cell control, c) a normal c-myc gene as compared to a non-tumorigenic Sprague-Dawley rat cell control, d) a normal c-fos gene as compared to a non-tumorigenic Sprague-Dawley rat cell control, e) a deregulated immediate early gene response, f) a canalicular network MATRIGEL.TM.

Abstract: The subject invention encompasses methods and compositions comprising N-acetylated amino acid complexes for reducing or preventing dental plaque, calculus, or gingival or periodontol diseases of the oral cavity in humans or lower animals.

Abstract: The present invention relates to a novel cell line isolated from a rat osteosarcoma wherein the cell line has the following characteristics: a) a normal p53 gene; b) a normal RB-1 gene; c) a normal c-myc gene; d) a normal c-fos gene; e) a deregulated immediate early gene response; f) a canalicular network MATRIGEL.TM. growth pattern; g) poorly tumorigenic in congenitally athymic mice; h) no alkaline phosphatase activity; i) an ability to produce one or more of the following growth factors: 1) a non-heparin binding growth factor, 2) a first heparin binding growth factor, 3) a second heparin binding growth factor, and 4) a third heparin binding growth factor; and j) an ability to be serially propagated greater than sixty population doublings.The present invention also relates to growth factors having the characteristics of growth factors isolated from the rat osteosarcoma cell line.

Abstract: The present invention relates to a novel cell line isolated from a rat osteosarcoma having the following characteristics: a) a normal p53 gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; b) a normal RB-1 gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; c) a normal c-myc gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; d) a normal c-fos gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; e) a normal immediate early gene response following mitogenic stimulation; f) a canalicular Matrigel growth pattern; g) non-tumorigenic in congenitally athymic mice; h) high levels of alkaline phosphatase activity; i) a lack of autocrine growth factor production; and j) an ability to be serially propagated greater than sixty population doublings.

Abstract: The present invention relates to a novel cell line isolated from a rat osteosarcoma cell line has the following characteristics: a) a non-expressed p53 protein; b) a normal RB-1 gene; c) a 1O.times. amplified c-myc gene; d) a normal c-fos gene; e) a deregulated immediate early gene response; f) a canalicular network MATRIGEL.TM. growth pattern; g) tumorigenic in congenitally athymic mice; h) no alkaline phosphatase activity; i) an ability to produce one or more of the following growth factors: 1) an osteoblastic differentiation growth factor, 2) a non-heparin binding mitogenic growth factor, 3) a first heparin binding mitogenic growth factor, 4) a second heparin binding mitogenic growth factor, and 5) a third heparin binding mitogenic growth factor; and an ability to be serially propagated greater than sixty population doublings.The present invention also relates to growth factors having the characteristics of growth factors isolated from the rat osteosarcoma cell line.

Abstract: The present invention relates to a novel cell line isolated from a rat osteosarcoma having the following characteristics: A) a non-expressed p53 protein; B) a normal RB-1 gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; C) a normal c-fos gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; D) a 50-fold amplified c-myc gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; E) a monolayer MATRIGEL.TM. growth pattern; F) tumorigenic in nude mice; G) normal alkaline phosphatase activity; H) an ability to be serially propagated greater than fifty population doublings; I) an ability to produce a growth factor selected from the group consisting of: 1) a mesenchymal inhibitory growth factor; 2) a non-heparin binding mitogenic growth factor; 3) a first heparin binding mitogenic growth factor; 4) a second heparin binding mitogenic growth factor; 5) a third heparin binding mitogenic growth factor; and 6) a fourth heparin binding mitogenic growth factor.